[1] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol, 2015, 62: 968-974.
[2] Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline For Acute Kidney Injury. Kidney Int, 2012, 2 (Suppl) :1-138.
[3] Belcher JM, Edelstein CL, Parikh CR. Clinical applications of biomarkers for acute kidney injury. Am J Kidney Dis, 2011, 57:930-940.
[4] Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury.Hepatology, 2014, 60:622-632.
[5] Huelin P, Solà E, Elia C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study.Hepatology, 2019, 70:319-333.
[6] Amin AA, Alabsawy EI,Jalan R,et al. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome. Semin Nephrol, 2019,39:17-30.
[7] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol,2018,69:406-460.
[8] Chawla LS, Bellomo R, Bihorac A, et al. Acute kindey disease and renal recovery: consensus report of the Acute Kidney Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol,2017,13:241-257.
[9] Angeli P,Garcia-Tsao G,Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol,2019 in press.
[10] Trebicka J, Amoros A, Pitarch C, et al. Addressing profiles of systemic infalmmation across the different clinical phenotypes of acutely decompensated cirrhosis. Front Immunol,2019,10 :476. eCollection 2019.
[11] Wiest R,Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol,2014,60:197-209.
[12] Maiwall R,Chandel SS,Wani Z,et al. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis. Dig Dis Sci,2016,61:920-929.
[13] Shah N, Mohamed FE, Jover-Cobos M,et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int,2013,33:398-409.
[14] Shah N, Dhar D, El Zahraa Mohammed F, Habtesion A, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol,2012,56:1047-1053.
[15] Mandorfer M, Hecking M. The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in liver disease. Hepatology,2019,69:1858-1860.
[16] Mattos AZ,Schacher FC,Mattos AA,et al. Vasoconstrictors in hepatorenal syndrome-A critical review. Ann Hepatol,2019,18:287-290.
[17] Nevens F, Bittencourt PL, Coenraad MJ, et al. Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Dig Dis Sci,2019,64:1419-1431.
[18] Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology,2015,62:567-574.
[19] Wong F, Leung W, Al Beshir M, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.2015,21:300-307.
[20] Nadim MK, Sung RS, Davis CL, et al. Simultaneous liver-kidney transplantation summit: current state and future directions.Am J Transplant,2012,12:2901-2908. |
